UNICREDIT BANK/CALL/BIOGEN IDEC/220/0.1/15.01.25 | Market Closed - Bid/Ask 03:41:59 2024-07-17 pm EDT | After market 03:59:59 pm | |||
| 2.74 EUR | +12.76% |
|
2.695 | -1.64% |
| Current month | -17.06% | ||
| 1 month | -23.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.74 | +12.76% |
| 24-07-16 | 2.43 | +6.11% |
| 24-07-15 | 2.29 | -15.50% |
| 24-07-12 | 2.71 | -13.69% |
| 24-07-11 | 3.14 | +9.41% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD31TH |
| ISIN | DE000HD31TH4 |
| Date issued | 2024-02-26 |
| Strike | 220 $ |
| Maturity | 2025-01-15 (182 Days) |
| Parity | 10 : 1 |
| Emission price | 3.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.52 € |
|---|---|
| Lowest since issue | 1.47 € |
| Spread | 0.05 € |
| Spread % | 1.83% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
225
USD
Average target price
281.2
USD
Spread / Average Target
+24.96%
- Stock Market
- Warrants
- Warrant
